TI
NVIV

Turner Investments’s InVivo Therapeutics Holdings Corp NVIV Stock Holding History

Turner Investments’s Portfolio NVIV Stock Details NVIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-5
Closed -$700K – 307
2016
Q3 		$700K Buy
+5
New +$624K 0.23% 129

Other funds holding NVIV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
WF
Welch & Forbes Boston, Massachusetts $8.23B AUM 17.62% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ICM
IMS Capital Management Portland, Oregon $217M AUM 18.69% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
GC
Guggenheim Capital Chicago, Illinois $12.9B AUM 27.3% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Turner Investments's NVIV Position: Q4 2016 in Review

Turner Investments sold out of InVivo Therapeutics Holdings Corp (NVIV) in Q4 2016, closing a stake of 5 shares — an estimated $700K sold.

Turner Investments first reported a position in NVIV in Q3 2016 and held it in 1 quarter. The position peaked at $700K in Q3 2016. 51 funds tracked by Wall St. Rank hold NVIV as of Q4 2016.

  • Turner Investments reported no remaining InVivo Therapeutics Holdings Corp position as of Q4 2016 after selling out during the quarter.
  • Turner Investments sold 5 InVivo Therapeutics Holdings Corp shares in Q4 2016, an estimated $700K.
  • Turner Investments first reported a position in InVivo Therapeutics Holdings Corp in Q3 2016 and held it in 1 quarter.
  • Turner Investments's InVivo Therapeutics Holdings Corp position peaked at $700K in Q3 2016.
  • 51 funds tracked by Wall St. Rank held InVivo Therapeutics Holdings Corp as of Q4 2016.

Based on Turner Investments's 13F filing for Q4 2016, filed 8 Feb 2017.